You are here

  • Home
  • Archive
  • Volume 11, Issue 1
  • Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

Article metrics

Article menu
Oncolytic and local immunotherapy
Original research
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: January 2023 to July 2025

AbstractFullPdf
Jan 2023374375134
Feb 2023290292115
Mar 202316916989
Apr 202315415672
May 202316616971
Jun 202311311352
Jul 202311711760
Aug 202317417649
Sep 2023929444
Oct 20239910141
Nov 202312112654
Dec 2023949547
Jan 2024919278
Feb 2024707445
Mar 2024939365
Apr 2024686942
May 2024747853
Jun 2024777746
Jul 202410610755
Aug 2024737132
Sep 2024808133
Oct 2024989953
Nov 2024909258
Dec 202410210457
Jan 2025727244
Feb 202519519563
Mar 2025959659
Apr 202514214276
May 2025888867
Jun 2025646440
Jul 2025220
Total364336791794